Zealand Pharma (ZLDPF) announced the establishment of a new research hub in Cambridge, Massachusetts, in the greater Boston area. The facility will serve as Zealand Pharma’s primary U.S. address and is expected to be operational from September 2026. “The Cambridge hub is a tangible commitment and an important addition to our research footprint – complementing the strong and active research already taking place in Denmark and marking another important step in our ambition to become a leader in obesity and metabolic health,” said Adam Steensberg, President and CEO of Zealand Pharma.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLDPF:
- Zealand Pharma price target lowered to DKK 275 from DKK 450 at Deutsche Bank
- Zealand Pharma price target lowered to DKK 460 from DKK 1,000 at JPMorgan
- Zealand Pharma downgraded to Neutral from Outperform at BNP Paribas
- Zealand Pharma downgraded to Market Perform from Outperform at William Blair
- Zealand Pharma downgraded to Neutral from Overweight at Cantor Fitzgerald